JPAD-Journal of Prevention of Alzheimers Disease

Article	Citations
Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report	260
Association of Cognitive Reserve Indicator with Cognitive Decline and Structural Brain Differences in Middle and Older Age: Findings from the UK Biobank	148
“Back to Braak”: Role of Nucleus Reuniens and Subcortical Pathways in Alzheimer's Disease Progression	136
Longitudinal Course of Agitation and Aggression in Patients with Alzheimer's Disease in a Cohort study: Methods, Baseline and Longitudinal Results of the A3C Study	123
Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid	62
The Scottish Brain Health Service Model: Rationale and Scientific Basis for a National Care Pathway of Brain Health Services in Scotland	48
Mechanisms Underlying Non-Pharmacological Dementia Prevention Strategies: A Translational Perspective	35
The Critical Role of Biomarkers for Drug Development Targeting the Biology of Aging	35
The Effect of Multidomain Interventions on Global Cognition, Symptoms of Depression and Apathy — A Pooled Analysis of Two Randomized Controlled Trials	29
Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging	26
Mendelian Randomization Analysis to Assess Whether Magnetic Resonance Imaging Signs of Cerebral Small Vessel Disease Can Cause Cognitive Decline and Dementia	24
Blood Cathepsins on the Risk of Alzheimer's Disease and Related Pathological Biomarkers: Results from Observational Cohort and Mendelian Randomization Study	23
The Relationship between History of Traumatic Brain Injury and Longitudinal Changes in Cortical Thickness among Patients with Alzheimer's Disease	23
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings	16
Neuroprotective Effects of IVIG against Alzheimer's Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice	16
Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial	15
Effectiveness of Resistance Exercise on Cognitive Function in Animal Models of Alzheimer Disease: A Systematic Review and Meta-Analysis	15
Longitudinal Cognitive Decline in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer's Disease	15
Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report	13
The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report	13
Consistency between Treatment Effects on Clinical and Brain Atrophy Outcomes in Alzheimer's Disease Trials	12
Burden of Illness in People with Alzheimer's Disease: A Systematic Review of Epidemiology, Comorbidities and Mortality	11
Associations of Blood Pressure Trajectories with Subsequent Cognitive Decline, Dementia and Mortality	11
Estimating Socio-Economic Status for Alzheimer's Disease Trials	11
Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force	10

Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease	10
Meta Analysis of the Correlation between Periodontal Health and Cognitive Impairment in the Older Population	10
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort	9
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data	9
Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review	9
Cognitive Performance and Incident Alzheimer's Dementia in Men Versus Women	9
Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease	8
Opportunities for Cellular Rejuvenation in Alzheimer's Disease: How Epigenetic Reprogramming and Chaperone-Mediated Autophagy Are Enabling Next Generation Therapeutic Approaches	8
Greater White Matter Hyperintensity Volume Is Associated with the Number of Microhemorrhages in Preclinical Alzheimer's Disease	8
Preferences about Future Alzheimer's Disease Treatments Elicited through an Online Survey Using the Threshold Technique	8
Universal Prevention of Dementia in Italy: A Document Analysis of the 21 Italian Regional Prevention Plans	8
Estimates of Current Capacity for Diagnosing Alzheimer's Disease in Sweden and the Need to Expand Specialist Numbers	8
The Role of Thyroid Dysfunction in Alzheimer's Disease: A Systematic Review and Meta-Analysis	8
Multidomain Intervention for the Reversal of Cognitive Frailty Using a Personalized Approach (AGELESS Trial): Recruitment and Baseline Characteristics of Participants	8
Update to: Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease	8
Heightened Prevalence of Common Hospital-Treated Infections Preceding Dementia Diagnosis with Accelerated Dementia Onset after Influenza	7
Evaluation of Clinical Meaningfulness of Fortasyn Connect in Terms of “Time Saved”	7
Progress in the Treatment of Alzheimer's Disease Is Needed – Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators	7
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration	7
Detection Rates of Mild Cognitive Impairment in Primary Care for the United States Medicare Population	7
Digital Health Technologies for Alzheimer's Disease and Related Dementias: Initial Results from a Landscape Analysis and Community Collaborative Effort	7
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations	7
The Clinical Trials Alzheimer's Disease (CTAD) Meeting in San Francisco, Fall 2022, Will Be a Very Exciting Event!	6
Alzheimer's Disease Prevention Health Coaching	6
Association of statins use and genetic susceptibility with incidence of Alzheimer's disease	6
Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study	6
Age, Sex, Hypertension and HDL-C Alter Serum BACE1 Activity in Cognitively Normal Subjects: Implications for Alzheimer's Disease	6
Corrigendum to “Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study” [The Journal of Prevention of Alzheimer's Disease 2024;11(3):567	6
American's overall and equity-based societal valuation of a disease-modifying Alzheimer's treatment: Results from a discrete choice experiment	6
Effects of Folic Acid and Vitamin B12 Supplementation on Cognitive Impairment and Inflammation in Patients with Alzheimer's Disease: A Randomized, Single-Blinded, Placebo-Controlled Trial	6
The effect of sleep disturbances on the incidence of dementia for varying lag times	6
A Novel Computerized Cognitive Stress Test to Detect Mild Cognitive Impairment	5
Standardizing Electronic Health Record Data on AD/ADRD to Accelerate Health Equity in Prevention, Detection, and Treatment	5
Ten Years after the National Alzheimer's Plan: Dementia Remains a Hidden Syndrome in France	5
Amnestic Mild Cognitive Impairment is Characterized by the Inability to Recover from Proactive Semantic Interference across Multiple Learning Trials	5
Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia	5
The Association between Peanut and Peanut Butter Consumption and Cognitive Function among Community-Dwelling Older Adults	5
Effects of Non-Invasive Brain Stimulation on Alzheimer's Disease	5
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats	5
Predictive Utility of Plasma Amyloid and Tau for Cognitive Decline in Cognitively Normal Adults	5
A Hierarchical Bayesian Latent Class Model for the Diagnostic Performance of Mini-Mental State Examination and Montreal Cognitive Assessment in Screening Mild Cognitive Impairment Due to Alzheimer's D	4
Association of Preeclampsia with Incident Dementia and Alzheimer's Disease among Women in the Framingham Offspring Study	4
Chronic Pain in Multiple Sites and Dementia: A Vicious Cycle?	4
The Effects of Dual-Task Training on Cognitive and Physical Functions in Older Adults with Cognitive Impairment; A Systematic Review and Meta-Analysis	4
Sex Difference in the Association between Prior Fracture and Subsequent Risk of Incident Dementia: A Longitudinal Cohort Study	4
Hypnotics and Incident Dementia: A Risk Assessment	4
Genetically Determined Alzheimer's Disease Is Associated with Increased Risk of Varicose Vein: A Mendelian Randomization Study	4
Digital Therapeutics for MCI and Alzheimer's disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer's Disease conference (CTAD)	4
Expanding the ATN Framework to Further Personalize Therapies	4
On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use	4

The Room Where It Happens: Clinician Reflections on Returning Preclinical Alzheimer's Biomarker Results to Research Participants	4
Cytomegalovirus Infection and Alzheimer's Disease: A Meta-Analysis	4
Balancing the Conflicting Goals for Treatment of Alzheimer's Disease with Monoclonal Antibodies	4
Objective and Subjective Measurements of Motor Function: Results from the HELIAD Study	4
Relationships of Hypnotics with Incident Dementia and Alzheimer's Disease: A Longitudinal Study and Meta-Analysis	4
Dietary Cholesterol and Dementia Risk	4
Usability of a Web-Based Registry for Preclinical Alzheimer's Disease: Implications from a Cross-Sectional Online Survey	4
Personalized Computational Causal Modeling of the Alzheimer Disease Biomarker Cascade	4
Translating the Biology of Aging into New Therapeutics for Alzheimer's Disease: Senolytics	3
Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease	3
Correlates of Subjective Cognitive Decline in Black American Men	3
Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform	3
The Shape Trail Test Is Sensitive in Differentiating Older Adults with Mild Cognitive Impairment: A Culture-neutral Five-minute Test	3
A Japanese Multicenter Study on PET and Other Biomarkers for Subjects with Potential Preclinical and Prodromal Alzheimer's Disease	3
The associations between fresh vegetable and fruit consumption and plasma and PET biomarkers in preclinical Alzheimer's disease: A cross-sectional and longitudinal study of Chinese population	3
Evaluating the Performance of Different Criteria in Diagnosing AD and Preclinical AD with the Bayesian Latent Class Model	3
Modifiable Risk Factors for Accelerated Decline in Processing Speed: Results from Three Dutch Population Cohorts	3
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217	3
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation	3
Expectancy Does Not Predict 18-month Treatment Outcomes with Cognitive Training in Mild Cognitive Impairment	3
Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force	3
Future of Alzheimer's Disease Treatment: Combination Therapy and Precision Medicine	3
The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT)	3
Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data	3
Computerized Cognitive Training in Mild Cognitive Impairment: Findings in African Americans and Caucasians	3
Beyond Frailty in Alzheimer's Disease: Should We Move to the Concept of Intrinsic Capacity?	3
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease	3
Association between Cerebrospinal Fluid sTREM2 Levels and Depression: The Alzheimer's Disease Neuroimaging Initiative Study	3
Anti-Hypertensives Reduce the Rate of Alzheimer's Disease Progression: A Cohort Study Linked with Genetic and Neuropathological Analyses	3
The Effects of Different Exercise Interventions on Patients with Subjective Cognitive Decline: A Systematic Review and Network Meta-Analysis	3
Nutrition-Based Approaches in Clinical Trials Targeting Cognitive Function: Highlights of the CTAD 2020	3
Editorial Board	3
Investigating the Factor Structure of the Preclinical Alzheimer Cognitive Composite and Cognitive Function Index across Racial/Ethnic, Sex, and Aβ Status Groups in the A4 Study	3
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease	3
Investigating the Impact of Tea Consumption on Cognitive Function and Exploring Tea-Genetic Interactions in Older Adults Aged 65–105 Years: Findings from the 2002–2018 CLHLS Data	3
Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program	3
Maintaining level of modifiable dementia risk scores is associated with better cognitive outcomes than increasing risk scores: A population-based prospective cohort study	3
Pushing through the Barriers: Peer Advice to Increase Physical Activity and Reduce Dementia Risk from Participants in a Massive Open Online Alzheimer's Focused Course	3
Informing Alzheimer's Biomarker Communication: Concerns and Understanding of Cognitively Unimpaired Adults During Amyloid Results Disclosure	3
Development and Validation the Mobile Toolbox (MTB) Spelling Test	3
Associations between Participant Characteristics and Participant Feedback about an Unsupervised Online Cognitive Assessment in a Research Registry	3
Outreach, Screening, and Randomization of APOE ε4 Carriers into an Alzheimer's Prevention Trial: A global Perspective from the API Generation Program	3
Protocol for the Brain Health Support Program Study of the Canadian Therapeutic Platform Trial for Multidomain Interventions to Prevent Dementia (CAN-THUMBS UP): A Prospective 12-Month Intervention St	3
The US Expert Panel on the Appropriate Use Recommendations of Aducanumab in Clinical Practice	3
Independent and Joint Associations of Socioeconomic Status and Lifestyle behaviors with Cognitive Impairment among Elderly Chinese Population	3
Validation, Deployment, and Real-World Implementation of a Modular Toolbox for Alzheimer's Disease Detection and Dementia Risk Reduction: The AD-RIDDLE Project	3
Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research	3
Artificial intelligence-enabled safety monitoring in Alzheimer's disease clinical trials	3
15th Conference Clinical Trials Alzheimer's Disease, November 29- December 2, 2022, San Francisco, CA, USA: Symposia - Oral Communications - Late Breaking Abstracts (Clinical Trial Alzheimer's Disease	3
Plasma Oligomer β-Amyloid and White Matter Microstructural Integrity in Cognitively Normal Older Adults According to Cerebral Amyloid Deposition	3
Aducanumab: Appropriate Use Recommendations Update	3
Cohort Effects in Alzheimer's Disease Trials: An Empirical Assessment Utilizing Data from the Alzheimer's Disease Cooperative Study	2
Aducanumab Trials EMERGE But Don't ENGAGE	2
Who Benefited Most from the Internet-Based Conversational Engagement RCT (I-CONECT)? Application of the Personalized Medicine Approach to a Behavioral Intervention Study	2
What Is Reasonable and Necessary for Alzheimer Patients from Randomized Clinical Trials to Clinical Practice?	2
Effects of the COVID-19 Pandemic on the Number of New Dementia Diagnoses and the Quality of Dementia Diagnostics and Treatment	2
Quantifying Recruitment Source and Participant Communication Preferences for Alzheimer's Disease Prevention Research	2
A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease	2
Validation of the multi-day Boston remote assessment of neurocognitive health (BRANCH) among cognitively impaired & unimpaired older adults	2
Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration	2
How Modifiable Are Modifiable Dementia Risk Factors? A Framework for Considering the Modifiability of Dementia Risk Factors	2
Periodontal Disease and Alzheimer's: Insights from a Systematic Literature Network Analysis	2
Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention	2
Childhood Secondhand Smoke Exposure and Risk of Dementia in Adulthood	2
US Adults' Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging	2
Non-Genetic Risk Factors of Alzheimer's Disease: An Updated Umbrella Review	2
A Large Retrospective Cohort Study on the Risk of Alzheimer's Disease and Related Dementias in Association with Vascular Diseases and Cancer Therapy in Men with Prostate Cancer	2
Psychometric Properties of the Clinical Dementia Rating — Sum of Boxes and other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population	2
Longitudinal Trajectories of the Cognitive Function Index in the A4 Study	2
When It Comes to Lecanemab (and Donanemab), How Might We Think about ‘Reasonable and Necessary'?	2
Effectiveness of a Meta-Cognitive Group Intervention for Older Adults with Subjective Cognitive Decline or Mild Cognitive Impairment: The ASPIRE Randomized Controlled Trial	2
Neuroinflammation Biomarkers in the AT(N) Framework Across the Alzheimer's Disease Continuum	2
Leveraging Diverse Regulated Cell Death Patterns to Identify Diagnosis Biomarkers for Alzheimer's Disease	2
Environmental Distractions during Unsupervised Remote Digital Cognitive Assessment	2
Aducanumab: Appropriate Use Recommendations	2
Cohort-Specific Optimization of Models Predicting Preclinical Alzheimer's Disease, to Enhance Screening Performance in the Middle of Preclinical Alzheimer's Disease Clinical Studies	2
Roles of TREM2 in the Pathological Mechanism and the Therapeutic Strategies of Alzheimer's Disease	2
AMBAR: A Therapeutical Approach for Alzheimer's Disease Patients Regardless of Amyloid Status	2
Fructose Consumption is Associated with a Higher Risk of Dementia and Alzheimer's Disease: A Prospective Cohort Study	2
Blood-Based Biomarkers for Alzheimer's Disease: Are We There Yet?	2

Dual Task Performance Is Associated with Amyloidosis in Cognitively Healthy Adults	2
Anxiety and Depressive Symptoms and Cortical Amyloid-β Burden in Cognitively Unimpaired Older Adults	2
Views and Perceptions of Amyloid Imaging in a Preclinical Alzheimer's Disease Trial	2
What Are the Remaining Challenges before Blood-Based Biomarkers for Alzheimer's Disease Can Be Used in Clinical Practice?	2
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment	2
Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease	2
Adding the Topographical Information from Tau-PET to the A/T/(N) Framework: Steps Towards Staging AD in Vivo	2
Cognitive Digital Biomarkers from Automated Transcription of Spoken Language	2
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force	2
Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force	2
Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable	2
Understanding Online Registry Facilitators and Barriers Experienced by Black Brain Health Registry Participants: The Community Engaged Digital Alzheimer's Research (CEDAR) Study	2
Metabolic Syndrome Status Changes and Cognitive Functioning: Insights from the Lifelines Cohort Study	2
Prevalence Estimation of Dementia/Alzheimer's Disease Using Health and Retirement Study Database in the United States	2
Site Readiness Framework to Improve Health System Preparedness for a Potential New Alzheimer's Disease Treatment Paradigm	2
Tau Pathologies Mediate the Associations of Vascular Risk Burden with Cognitive Impairments in Non-demented Elders: The CABLE Study	2
Study Protocol of a Comprehensive Activity Promotion Program for the Prevention of Dementia: A Randomized Controlled Trial Protocol	2
Prediction of Cognitive Decline for Enrichment of Alzheimer's Disease Clinical Trials	2
Sex Moderates the Association between Frailty and Mild Behavioral Impairment	2